Compare Abbott Laboratories (ABT) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs LyondellBasell Industries NV — how do they compare? Abbott Laboratories trades at $95.52 (market cap $166.94B), while LyondellBasell Industries NV trades at $56.1 (market cap $17.62B). The key difference: Abbott Laboratories is far larger — about 9.5× LyondellBasell Industries NV's market cap, and LyondellBasell Industries NV pays the higher dividend (7.55%). Which is the better fit depends on your goals.
| ABT | LYB | |
|---|---|---|
Market Cap | $166.94B | $17.62B |
Sector | Health | Basic Materials |
52-Week High | $136.62 | $82.38 |
52-Week Low | $82.57 | $42.28 |
Enterprise Value | $193.69B | $29.24B |
Dividend Yield | 2.63% | 7.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
LyondellBasell (LYB) trades at $54.61, up 2.33% on the day, with a bearish technical signal but oversold RSI readings. The company reported a net loss of -$745M in 2025 with revenue declining to $30.15B, though it beat EPS estimates in two of the last three quarters. Recent news highlights a packaging collaboration with Mondelez and upcoming Q2 2026 earnings on July 31. Cash flow remains positive with $61M net inflow in 2025, while debt-to-asset ratio increased to 38.18%.
Outlook is mixed: analyst consensus price target of $73.11 suggests 34% upside, supported by cost-cutting and recycling initiatives, but persistent margin pressures and high debt pose risks. Investors should weigh the value opportunity (P/S of 0.57) against earnings volatility and sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
